Last Updated: January 2nd, 2026
Decision-making across complex pipelines involves balancing clinical positioning, market access potential, pricing expectations, and health technology assessment requirements. A systematic assessment framework supports early alignment, improves prioritization, and informs investment decisions with confidence.
Technical Expertise Supporting Assessment Strategy
Reviewing Development Profiles
Each asset’s development profile is reviewed to assess assumptions that underpin strategic positioning and feasibility.
Assessing Market Access Environment
Key market access factors are reviewed, including access landscape and relevant system considerations that may influence future decisions.
Considering HTA Requirements
HTA considerations are incorporated to reflect how evidence and value may be assessed during future evaluations.
Practical Agility Supporting Decision Delivery
Establishing Access and Pricing Implications
Market access and pricing implications are established across relevant domains to support strategic evaluation.
Identifying Value Drivers
Key value drivers are identified from assessment parameters to inform ‘Go’ or ‘No Go’ considerations across the portfolio.
Quantifying Market Value
Pricing calculations are developed using value-based approaches to support understanding of potential market value.
Summarizing Go- or No-Go Direction
A structured summary indicates the relative favorability of each asset across key domains, supporting informed decision-making.
Identifying Evidence Needs
Evidence requirements are identified, and activities are recommended to address data gaps and support future decisions.
Customer Testimonies
Our Expert Support
Applying a structured Go- or No-Go assessment enables teams to prioritize assets effectively, allocate resources where they add the most value, and reduce uncertainty in pipeline decision-making. This supports more efficient development and increases alignment across clinical, access, and commercial strategies. Connect with our expert team for assessment assistance.
Learn how Go- or No-Go assessment supports strategic pipeline planning
Meet our Value Communications Team
Mike Blackney
Head of Operations
Mike is responsible for overseeing operational strategies at FIECON, ensuring the delivery of first-class results and client satisfaction. With more than fifteen years of experience in market access and pricing, Mike has worked with leading global pharmaceutical companies on key access-based projects.
Susan Suponcic
Strategic Council Member
Susan is a market access executive with over 25 years of experience in pricing, health economics, and market access roles across both corporate and consulting environments. She has led market access strategies for global launches in virology and oncology, delivering over $3 billion in revenues in under five years.
FAQs on Go- or No-Go Assessments
What is a Go- or No-Go assessment?
A Go- or No-Go assessment evaluates whether a pipeline asset should advance or be reprioritized based on evidence needs, access potential, and strategic fit.When is a Go- or No-Go assessment most valuable?
It is most valuable early in development and at key decision points where teams are setting priorities or allocating resources.What factors are considered in the assessment?
Factors include clinical positioning, competitive environment, pricing and access conditions, HTA expectations, and evidence gaps.How does this assessment support strategic planning?
It helps teams prioritize assets, identify risks and opportunities, and align development and access plans with expected future requirements.